Exercise in a pill? That's the focus of Cambrian's new pipeline company
In line with its anti-aging central theme, Cambrian BioPharma has a new clinical candidate to work with, going after what CEO James Peyer described as a “Holy Grail target.”
The New York drug developer announced the launch of its newest pipeline company, Amplifier Therapeutics, Tuesday morning. Cambrian is investing $26 million into Amplifier to kick things off, Peyer told Endpoints News. James Hall, the ex-head of cardiovascular BD at AstraZeneca, is at the helm as Amplifier’s CEO.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.